Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
To the Editor: The study by Dr Simon and colleagues1 appears to provide evidence for the efficacy and
safety of celecoxib, a cyclooxygenase 2 (COX-2) inhibitor. However, several
aspects of their experimental design appear to limit these conclusions.
First, it is most useful to compare a new agent with the most effective
and least toxic existing agent. Although the authors chose naproxen as the
comparison drug, other nonsteroidal anti-inflammatory drugs (NSAIDs), such
as ibuprofen2,3 and nabumetone,4 have less gastrointestinal (GI) tract toxicity.
Also, they began treatment of the comparison group with 500 mg twice per day
of naproxen, which is the maximum suggested initial dosage.5
This is especially troubling because about 40% of this group was older than
60 years and, thus, had a 3-fold risk of NSAID-induced gastropathy.3,6
Fernandez H, Lesser GT. Cyclooxygenase 2 Selective Agents and Upper Gastrointestinal Disease. JAMA. 2000;283(15):1961-1962. doi:10.1001/jama.283.15.1957